Literature DB >> 18248700

A sample of Canadian orthopedic surgeons expressed willingness to participate in osteoporosis management for fragility fracture patients.

Earl R Bogoch1, Elizabeth Snowden.   

Abstract

OBJECTIVE: The orthopedic community is in a unique position to initiate and provide osteoporosis care in fragility fracture patients to prevent future hip fractures in a high-risk population. The attitudes and intentions of Canadian orthopedic surgeons in the domain of osteoporosis care are unknown. Our objective was to identify current attitudes and osteoporosis management practices and to determine their overall willingness to participate in osteoporosis care for fragility fracture patients.
METHODS: A real-time interactive polling session was conducted at the 58th Annual Meeting of the Canadian Orthopaedic Association.
RESULTS: Of the orthopedic surgeons who responded, 90.4% agreed that the current emphasis on osteoporosis in orthopedic practice is appropriate; 85.2% of surgeons indicated that they currently refer or personally investigate for osteoporosis, or both, in fragility fracture patients.
CONCLUSION: Most of the Canadian orthopedic surgeons sampled consider themselves to be currently engaged or ready to engage in osteoporosis care for fragility fracture patients. Focus should now shift from education and persuasion to program support through provision of resources and system modification that will enable Canadian orthopedic surgeons to effectively manage osteoporosis in their fracture patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18248700      PMCID: PMC2386310     

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  21 in total

1.  Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.

Authors:  D M Black; D E Thompson; D C Bauer; K Ensrud; T Musliner; M C Hochberg; M C Nevitt; S Suryawanshi; S R Cummings
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

2.  Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date.

Authors:  Anthony B Hodsman; David A Hanley; Robert Josse
Journal:  CMAJ       Date:  2002-05-28       Impact factor: 8.262

Review 3.  Why most interventions to improve physician prescribing do not seem to work.

Authors:  Sumit R Majumdar; Stephen B Soumerai
Journal:  CMAJ       Date:  2003-07-08       Impact factor: 8.262

Review 4.  2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.

Authors:  Jacques P Brown; Robert G Josse
Journal:  CMAJ       Date:  2002-11-12       Impact factor: 8.262

5.  Economic implications of hip fracture: health service use, institutional care and cost in Canada.

Authors:  M E Wiktorowicz; R Goeree; A Papaioannou; J D Adachi; E Papadimitropoulos
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

Review 6.  Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women.

Authors:  Ann Cranney; George Wells; Andrew Willan; Lauren Griffith; Nicole Zytaruk; Vivian Robinson; Dennis Black; Jonathan Adachi; Beverley Shea; Peter Tugwell; Gordon Guyatt
Journal:  Endocr Rev       Date:  2002-08       Impact factor: 19.871

Review 7.  Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis.

Authors:  Ann Cranney; Peter Tugwell; Jonathan Adachi; Bruce Weaver; Nicole Zytaruk; Alexandra Papaioannou; Vivian Robinson; Beverley Shea; George Wells; Gordon Guyatt
Journal:  Endocr Rev       Date:  2002-08       Impact factor: 19.871

8.  Limb fractures in elderly men as indicators of subsequent fracture risk.

Authors:  Bruce Ettinger; G Thomas Ray; Alice R Pressman; Oscar Gluck
Journal:  Arch Intern Med       Date:  2003 Dec 8-22

Review 9.  Colles fracture, spine fracture, and subsequent risk of hip fracture in men and women. A meta-analysis.

Authors:  Patrick Haentjens; Philippe Autier; John Collins; Brigitte Velkeniers; Dirk Vanderschueren; Steven Boonen
Journal:  J Bone Joint Surg Am       Date:  2003-10       Impact factor: 5.284

10.  Undertreatment with anti-osteoporotic drugs after hospitalization for fracture.

Authors:  Martien J M Panneman; Paul Lips; Shuvayu S Sen; Ron M C Herings
Journal:  Osteoporos Int       Date:  2003-11-13       Impact factor: 4.507

View more
  2 in total

1.  Canadian orthopedic surgeons and postfracture osteoporosis care: moving from persuasion toward facilitation.

Authors:  Earl R Bogoch
Journal:  Can J Surg       Date:  2008-02       Impact factor: 2.089

2.  Surgeon Specialty Influences Referral Rate for Osteoporosis Management following Vertebral Compression Fractures.

Authors:  Scott D Daffner; Jonathan M Karnes; Colleen M Watkins
Journal:  Global Spine J       Date:  2015-11-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.